<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201128049510N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-07</date_registration>
      <primary_sponsor>University of Mohaghegh Ardabili</primary_sponsor>
      <public_title>The effect of exercise and Mulberry leaf extract on some cardiovascular inflammatory markers in the elderly with type 2 diabetes</public_title>
      <acronym>-</acronym>
      <scientific_title>The effect of combined exercises and the consumption of Mulberry leaf extract on the serum levels of alpha and beta salucin and some related inflammatory or cardiovascular markers in elderly men with type 2 diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-17</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66892</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this research, the subjects are selected by simple random with the rule of random allocation. Thus, after determining the sample size, people will be equally placed in five groups (1-exercise, 2-exercise+supplement, 3- supplement, 4- placebo and 5- control). Using the lottery method, the names of the subjects are written on separate papers and placed in a container. Then the names of the subjects will be taken out randomly and they will be placed in the intervention, placebo and control groups respectively.</study_design>
      <phase>3</phase>
      <hc_freetext>Type 2 diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group 1: Combined exercise (aerobic and resistance): Aerobic exercises will be performed for 10 to 30 minutes with an intensity between 50 and 70% of the maximum heart rate. Resistance exercises for 30 to 40 minutes with an intensity between 40 and 70 percent of a maximum repetition will be performed by the subjects. Intervention 2: Intervention group: Intervention group 2: Supplement group + daily exercise will consume 1000 mg (2 capsules of 500 mg), Mulberry leaf extract , 3 times a day along with combined exercises. Intervention 3: Intervention group: Intervention 3: The daily supplement group will take 1000 mg (2 capsules of 500 mg) of Mulberry leaf extract, 3 times a day. Intervention 4: Intervention group: Intervention 4: The placebo group will take 1000 mg daily (2 capsules of 500 mg), containing wheat flour, 3 times a day. Intervention 5: Control group: The control group will not participate in any exercise program.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The personal data of the study participants can be shared after de-identification

When:
Three months after the results are published

To whom:
researchers

Conditions:
In order to be more transparent and under the consent of the researcher

Where to obtain:
Mohammad Ebrahim Bahram

How to obtain:
Request and send to the researcher

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Roghayyeh Afroundeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ardabil, University Street, University of Mohaghegh Ardabili</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8599156189</zip>
        <telephone>+98 45 3150 5193</telephone>
        <email>afroundeh@uma.ac.ir</email>
        <affiliation>University of Mohaghegh Ardabili</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Roghayyeh Afroundeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ardabil, University Street, University of Mohaghegh Ardabili</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5619911367</zip>
        <telephone>+98 45 3150 5626</telephone>
        <email>afroundeh@uma.ac.ir</email>
        <affiliation>University of Mohaghegh Ardabili</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having type 2 diabetes between one and 10 years
Not taking more than one type of oral anti-diabetic pill at night
Having a basic level of glycosylated hemoglobin between 6.6 and 9.9%
Having a fasting blood glucose of 160 to 250 mg/dL
Ability to do sports
Not participating in a regular exercise program for at least 6 months before the start of the study</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>70 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Taking more than one type of oral anti-diabetic pill at night
Smoking
having cardiovascular, kidney and eye diseases, complications of diabetes (neuropathy, nephropathy, retinopathy)
Treated with insulin</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group 1: Combined exercise (aerobic and resistance): Aerobic exercises will be performed for 10 to 30 minutes with an intensity between 50 and 70% of the maximum heart rate. Resistance exercises for 30 to 40 minutes with an intensity between 40 and 70 percent of a maximum repetition will be performed by the subjects.</i_keyword>
      <i_keyword>Intervention group: Intervention group 2: Supplement group + daily exercise will consume 1000 mg (2 capsules of 500 mg), Mulberry leaf extract , 3 times a day along with combined exercises.</i_keyword>
      <i_keyword>Intervention group: Intervention 3: The daily supplement group will take 1000 mg (2 capsules of 500 mg) of Mulberry leaf extract, 3 times a day.</i_keyword>
      <i_keyword>Intervention group: Intervention 4: The placebo group will take 1000 mg daily (2 capsules of 500 mg), containing wheat flour, 3 times a day.</i_keyword>
      <i_keyword>Control group: The control group will not participate in any exercise program.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Salusin alpha. Timepoint: 24 hours before and 48 hours after training. Method of measurement: Blood sampling and using a laboratory kit.</prim_outcome>
      <prim_outcome>Salusin beta. Timepoint: 24 hours before and 48 hours after training. Method of measurement: Blood sampling and using a laboratory kit.</prim_outcome>
      <prim_outcome>Lipocalin 2. Timepoint: 24 hours before and 48 hours after training. Method of measurement: Blood sampling and using a laboratory kit.</prim_outcome>
      <prim_outcome>Galectin 3. Timepoint: 24 hours before and 48 hours after training. Method of measurement: Blood sampling and using a laboratory kit.</prim_outcome>
      <prim_outcome>Interleukin 6. Timepoint: 24 hours before and 48 hours after training. Method of measurement: Blood sampling and using a laboratory kit.</prim_outcome>
      <prim_outcome>Interleukin 1 beta. Timepoint: 24 hours before and 48 hours after training. Method of measurement: Blood sampling and using a laboratory kit.</prim_outcome>
      <prim_outcome>Insulin. Timepoint: 24 hours before and 48 hours after training. Method of measurement: Blood sampling and using a laboratory kit.</prim_outcome>
      <prim_outcome>Glucose. Timepoint: 24 hours before and 48 hours after training. Method of measurement: Blood sampling and using a laboratory kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Mohaghegh Ardabili</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-04-25</approval_date>
        <contact_name>Ethics Committee of Mohaghegh Ardabili University, Faculty of Educational Sciences and Psychology</contact_name>
        <contact_address>Ardabil, University Street, University of Mohaghegh Ardabili Ardabil Ardabil Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
